HC Wainwright Reaffirms “Buy” Rating for Lexicon Pharmaceuticals (NASDAQ:LXRX)
Lexicon Pharmaceuticals (NASDAQ:LXRX – Get Free Report)‘s stock had its “buy” rating reiterated by stock analysts at HC Wainwright in a research report issued on Tuesday,Benzinga reports. They currently have a $4.00 target price on the biopharmaceutical company’s stock. HC Wainwright’s target price would indicate a potential upside of 344.44% from the stock’s current price. […]
Lexicon Pharmaceuticals (NASDAQ:LXRX – Get Free Report)‘s stock had its “buy” rating reiterated by stock analysts at HC Wainwright in a research report issued on Tuesday,Benzinga reports. They currently have a $4.00 target price on the biopharmaceutical company’s stock. HC Wainwright’s target price would indicate a potential upside of 344.44% from the stock’s current price. […]
